LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial
Stocks in this Quantisnow insightHealth Care
Historical context for LIXT
Across the 6 sessions after earlier LIXT headlines, the stock closed higher 3 times and lower 3 times, with a median move of 2.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | LIXT | SPY |
|---|---|---|---|
| Dec 23, 2025 | Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $4.3 Million Registered Direct Offering | -1.9% | +0.5% |
| Dec 18, 2025 | Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules | -1.0% | +0.8% |
| Dec 8, 2025 | LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities | +7.2% | -0.3% |
| Dec 3, 2025 | LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncologyand 1 other headline that session | +3.4% | +0.3% |
| Nov 25, 2025 | LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment | -8.5% | +0.9% |
| Oct 29, 2025 | LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3 | +1.6% | +0.0% |
Quantisnow market dataNASDAQ
LIXT
Lixte Biotechnology Holdings Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for LIXT
Full LIXT profile on Quantisnow Follow LIXT and get a push notification the moment its next story breaks.